YS Biopharma Co., Ltd.
YS · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | -0.01 | -0.00 | 33.38 |
| FCF Yield | -25.03% | -60.57% | -28.16% | -16.49% |
| EV / EBITDA | -19.39 | -2.00 | -12.75 | -32.69 |
| Quality | ||||
| ROIC | -9.15% | -41.04% | -11.07% | -0.17% |
| Gross Margin | 82.47% | 79.48% | 77.68% | 76.72% |
| Cash Conversion Ratio | 1.21 | 0.68 | 1.25 | 1.12 |
| Growth | ||||
| Revenue 3-Year CAGR | -3.63% | 4.47% | 38.80% | 7,952,483.55% |
| Free Cash Flow Growth | 59.10% | -41.73% | 20.04% | 14.78% |
| Safety | ||||
| Net Debt / EBITDA | -7.96 | -0.48 | -1.67 | -5.65 |
| Interest Coverage | -5.48 | -10.05 | -4.52 | -0.20 |
| Efficiency | ||||
| Inventory Turnover | 0.47 | 0.58 | 0.83 | 0.70 |
| Cash Conversion Cycle | 900.81 | 705.33 | 498.44 | 647.01 |